A patient with oligometastatic hormone‐sensitive prostate cancer who achieved long‐term progression‐free survival following cytoreductive radical prostatectomy and metastasectomy

• Published in: IJU case reports Vol. 7; no. 2; pp. 165 - 168
• Main Authors: Mamiya, Daisuke, Kijima, Toshiki, Takada‐Owada, Atsuko, Kokubun, Hidetoshi, Uematsu, Toshitaka, Takei, Kohei, Kambara, Tsunehito, Ishida, Kazuyuki, Taneichi, Hiroshi, Kamai, Takao
• Format: Journal Article
• Language: English
• Published: Australia John Wiley & Sons, Inc 01.03.2024; John Wiley and Sons Inc; Wiley
• Subjects: Androgens; Bone marrow; Cancer therapies; Case Report; Case Reports; Conflicts of interest; cytoreductive surgery; Fractures; Lymphatic system; Magnetic resonance imaging; Medical prognosis; metastasectomy; Metastasis; oligometastasis; Patients; progression‐free survival; Prostate cancer; Radiation therapy; Scintigraphy; Supervision; Tomography; Writing; prostate cancer; oligometastasis; metastasectomy; cytoreductive surgery; progression‐free survival
• ISSN: 2577-171X; 2577-171X
• DOI: 10.1002/iju5.12693

Introduction Oligometastatic prostate cancer can be well‐controlled through combined local and metastasis‐directed therapies. However, the effects of cytoreductive radical prostatectomy and metastasectomy remain unclear. Case presentation A 52‐year‐old man presented with prostate cancer and isolated bone metastasis to the thoracic spine. Six months after neoadjuvant hormonal therapy, the patient underwent cytoreductive radical prostatectomy and total en bloc spondylectomy. The postoperative course was uneventful. Hormonal therapy was terminated 5 years after surgery, and no biochemical or radiological progression was observed at 7 years postoperatively. Conclusion Although careful patient selection is necessary, cytoreductive radical prostatectomy and metastasectomy are effective treatments for well‐selected patients with oligometastatic prostate cancer.